On December 12, 2025, Merus N.V. (MRUS) completed its acquisition by Genmab A/S and Genmab Holding II B.V. The 8-K filing disclosed that Genmab acquired 94.2 percent of Merus N.V.'s outstanding common shares for $97.00 per share, representing total aggregate consideration of approximately $6.9 billion.

The acquisition, governed by a Transaction Agreement dated September 29, 2025, resulted in a change in control of Merus N.V., according to the filing. The Offer to Purchase was dated October 21, 2025, and the Offer expired on December 11, 2025. A Subsequent Offering Period is scheduled to expire on December 29, 2025.

Following the acquisition, several directors and executives of Merus N.V. ceased to hold their positions. Former Director and Executive Officer Sven (Bill) Ante Lundberg, M.D., former directors Mark Iwicki, Len Kanavy, Paolo Pucci, Victor Sandor, M.D., and Jason Haddock, and former executive officer Peter Silverman all departed, the filing states. Directors Maxine Gowen, Ph.D. and Anand Mehra, M.D. remained in their positions.

New leadership appointments include Jan van de Winkel, Ph.D. as Chief Executive Officer and non-executive directors Greg Mueller, Anthony Pagano, and Martine van Vugt, Ph.D., according to the filing. The company referenced Exhibit 2.1 for details of the Transaction Agreement and Exhibit 10.1 for details of a Gross-Up Agreement for executives regarding potential excise taxes.